Combination therapy with sulfonylureas and metformin and the prevention of death in type 2 diabetes: A nested case-control study

Pharmacoepidemiology and Drug Safety

Volumn 19, Issue 4, 2010, Pages 335-342

  Azoulay, Laurent ^a,b   Schneider Lindner, Verena ^a,b   Dell'Aniello, Sophie ^a   Schiffrin, Alicia ^a   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Combination therapy; Metformin; Mortality; Sulfonylureas

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN; SULFONYLUREA;

AGED; ARTICLE; CASE CONTROL STUDY; CAUSE OF DEATH; CONTROLLED STUDY; DRUG DETERMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME;

CASE-CONTROL STUDIES; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GREAT BRITAIN; HUMANS; HYPOGLYCEMIC AGENTS; LOGISTIC MODELS; MALE; METFORMIN; MIDDLE AGED; MORTALITY; RISK; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 77950874655     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1834     Document Type: Article

References (31)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
2. Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet 1998; 352: 832-833. (Pubitemid 28416714)
3. Olsson J, Lindberg G, Gottsater M, et al. Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 2000; 43: 558-560. (Pubitemid 30322072)
4. Johnson JA, Majumdar SR, Simpson SH, Toth EL. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
5. Mannucci E, Monami M, Masotti G, Marchionni N. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides. Diabetes Metab Res Rev 2004; 20: 44-47. (Pubitemid 38196247)
6. Gulliford M, Latinovic R. Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 2004; 20: 239-245. (Pubitemid 38714323)
7. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med 2005; 22: 497-502.
8. Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006; 49: 930-936.
9. Kahler KH, Rajan M, Rhoads GG, et al. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration. Diabetes Care 2007; 30: 1689-1693. (Pubitemid 47036337)
10. Gosmanova EO, Canada RB, Mangold TA, Rawls WN, Wall BM. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus. Am J Med Sci 2008; 336: 241-247.
11. Fisman EZ, Tenenbaum A, Boyko V, et al. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 2001; 24: 151-158. (Pubitemid 32108625)
12. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-causemortality?: ameta-analysis of observational studies. Diabetes Care 2008; 31: 1672-1678.
13. Lund SS, Rossing P, Vaag A, et al. Follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2009; 360: 416-418.
14. Walley T, Mantgani A. The UK general practice research database. Lancet 1997; 350: 1097-1099.
15. Garcia Rodriguez LA, Perez GS. Use of the UK general practice research database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-425. (Pubitemid 28227341)
16. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302: 766-768.
17. Lawrenson R,Williams T, Farmer R. Clinical information for research; the use of general practice databases. J Public Health Med 1999; 21: 299-304. (Pubitemid 29446069)
18. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000; 49: 591-596. (Pubitemid 30326559)
19. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy 2003; 23: 686-689. (Pubitemid 36539051)
20. Suissa S. Novel approaches to pharmacoepidemiology study design and statistical analysis. In Pharmacoepidemiology, Strom B (ed.). John Wiley & Sons: Chichester, England, 2005; 811-829.
21. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of timedependent exposure. BMC Med Res Methodol 2005; 5: 5.
22. Essebag V, Genest J, Jr, Suissa S, Pilote L. The nested case-control study in cardiology. Am Heart J 2003; 146: 581-590.
23. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008; 359: 1565-1576.
24. Panten U, Schwanstecher M, Schwanstecher C. Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diabetes 1996; 104: 1-9.
25. Towler MC, Hardie DG. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007; 100: 328-341. (Pubitemid 46272405)
26. Pantalone KM, Kattan MW, Yu C, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 2009; 46: 145-154.
27. McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 2008; 10: 703-708.
28. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070-2080.
29. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol 2003; 158: 915-920. (Pubitemid 37323253)
30. Benoit SR, Fleming R, Philis-Tsimikas A, Ji M. Predictors of glycemic control among patients with type 2 diabetes: a longitudinal study. BMC Public Health 2005; 5: 36. (Pubitemid 40923604)
31. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. (Pubitemid 28350165)